Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Cash from financing is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders.
For the
three
months ended in Mar. 2026,
Episurf Medical AB receivedkr13.50 Mil more from issuing new shares than it paid to buy back shares.
It spentkr0.10 Mil paying down its debt.
It paidkr0.00 Mil more to buy back preferred shares than it received from issuing preferred shares.
It receivedkr0.00 Mil from paying cash dividends to shareholders.
It spentkr9.70 Mil on other financial activities.
In all, Episurf Medical ABearnedkr3.70 Mil on financial activities for the
three
months ended in Mar. 2026.
Episurf Medical AB (LTS:0QUT) Cash Flow from Financing Explanation
Cash from financing contains six items:
1. Issuance of Stock:
A company may raise cash from issuing new shares. Issuance of stock represents the cash inflow from offering common stock, which is the additional capital contribution to the entity during the period.
Episurf Medical AB's issuance of stock for the
three
months ended in Mar. 2026 was kr13.50 Mil.
2. Repurchase of Stock:
A company may raise cash from issuing new shares. It can also use cash to buy back shares. Repurchase of stock represents the cash outflow to reacquire common stock during the period.
Episurf Medical AB's repurchase of stock for the
three
months ended in Mar. 2026 was kr0.00 Mil.
3. Net Issuance of Debt:
Net issuance of debt is the cash a company received or spent through debt related activities such as debt issuance or debt repayment. If a company pays down its debt during the period, this number will be negative. If a company issued more debt, it receives cash and this number is positive.
Episurf Medical AB's net issuance of debt for the
three
months ended in Mar. 2026 was kr-0.10 Mil.
Episurf Medical AB spentkr0.10 Mil paying down its debt.
4. Net Issuance of Preferred Stock:
A company may raise cash from issuing new preferred shares. It can also use cash to buy back preferred shares. If this number is positive, it means that the company has received more cash from issuing preferred shares than it has paid to buy back preferred shares. If this number is negative, it means that company has paid more cash to buy back preferred shares than it has received for issuing preferred shares.
Episurf Medical AB's net issuance of preferred for the
three
months ended in Mar. 2026 was kr0.00 Mil.
Episurf Medical AB paidkr0.00 Mil more to buy back preferred shares than it received from issuing preferred shares.
5. Cash Flow for Dividends:
Cash flow for dividends refers to the payment of cash to shareholders as dividends when the company generates income.
Episurf Medical AB's cash flow for dividends for the
three
months ended in Mar. 2026 was kr0.00 Mil.
Episurf Medical AB receivedkr0.00 Mil from paying cash dividends to shareholders.
6. Other Financing:
Money spent or earned by company from other financial activities.
Episurf Medical AB's other financing for the
three
months ended in Mar. 2026 was kr-9.70 Mil.
Episurf Medical AB spentkr9.70 Mil on other financial activities.
Episurf Medical AB Cash Flow from Financing Related Terms
Episurf Medical AB Cash Flow from Financing Historical Data
* Premium members only.
The historical data trend for Episurf Medical AB's Cash Flow from Financing can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Episurf Medical AB Cash Flow from Financing Calculation
This is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders. In the calculation of free cash flow, cash from financing is not calculated because it is not related to operating activities.
Episurf Medical AB's Cash from Financing for the fiscal year that ended in Dec. 2025 is calculated as:
Cash Flow from Financing for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was kr21.80 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Cash Flow from Financing of kr21.80 Mil mean?
Episurf Medical AB (LTS:0QUT) has a Cash Flow from Financing of kr21.80 Mil as of Mar. 2026. Cash Flow from Financing is the amount of cash earned or paid from financing operations. View historical data for Episurf Medical AB and its competitors.
Is Episurf Medical AB's Cash Flow from Financing too high?
Episurf Medical AB's current Cash Flow from Financing is kr21.80 Mil.
How does Episurf Medical AB's Cash Flow from Financing compare to ABT and SYK?
Episurf Medical AB's Cash Flow from Financing of kr21.80 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Flow from Financing for a Medical Devices & Instruments company?
A good Cash Flow from Financing depends on the Medical Devices & Instruments industry context. However, Cash Flow from Financing should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Flow from Financing mean?
A high Cash Flow from Financing can signal that a stock is expensive relative to its fundamentals. Cash Flow from Financing is the amount of cash earned or paid from financing operations. View historical data for Episurf Medical AB and its competitors. Episurf Medical AB's current Cash Flow from Financing is kr21.80 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Episurf Medical AB stock overvalued right now?
Based on GuruFocus' analysis, Episurf Medical AB (LTS:0QUT) is currently considered Modestly Overvalued. The stock's GF Value™ is kr0.05, compared to a current price of kr0.06 — trading 13% above its estimated fair value. The current Cash Flow from Financing is kr21.80 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Flow from Financing calculated?
Cash Flow from Financing is calculated from a company's financial statements. For Episurf Medical AB (LTS:0QUT), the current Cash Flow from Financing is kr21.80 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Episurf Medical AB is a medical device company. The company develops, manufactures, and commercializes solutions for the repair of the local cartilage damage in human joints. Its first patient-specific product portfolio, the knee portfolio, consists of the existing products Episealer Condyle Solo and Episealer Trochlea Solo, Episealer Femoral Twin, Epiguide MOS, and Epioscopy. Episealer Patellofemoral System for the treatment of osteoarthritis limited to thepatellofemoral part of the knee joint. The company is forming a new strategic business segment through the acquisition of real estate assets.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LTS:0QUT has been successfully added to your 
